The management of patients with hypertrophic cardiomyopathy (HCM) has evolved markedly over the past 20 years, particularly with the rising number of indications for implantable cardiac defibrillators (ICDs) and alcohol septal ablation (ASA). However, medical therapies targeted to improve quality of life are underused; when resting and/or exercise obstruction is present, an incremental and additive approach should be used based on a high dosage of beta-blockers, verapamil and/or disopyramide. Radiofrequency catheter ablation of atrial fibrillation or A-V node has been proposed in some instances. Treatment of syncope or presyncope due to an abnormal blood pressure response during exercise remains challenging. Only patients with obstruction who remain severely symptomatic despite maximal medical therapy should be considered for invasive procedures, including dual-chamber (DDD) pacing, ASA or surgery. The reported complication rates of ASA (essentially complete A-V block, incidence above 5-10%, with mortality rates ranging from 0-4%) and the benefits at medium-term followup appear comparable to those observed after myectomy, which, according to guidelines, should remain the primary treatment for most severely symptomatic drug-refractory young patients with obstruction. While the overall survival of patients with HCM is similar to that of the general population, detection of patients at high risk of sudden cardiac death remains challenging, particularly in the young, and indications for ICDs in high risk patients without prior cardiac arrest should be patient-and family-orientated. (AS). Cependant, les traitements médicaux ayant pour but d'améliorer la qualité de vie sont souvent sous-employés. Lorsqu'une obstruction est présente au repos ou à l'effort, une approche incrémentielle et additive devrait être employée, basée sur de fortes posologies de bêtabloquants, vérapamil et/ou disopyramide. L'ablation par radiofréquence d'une fibrillation auriculaire ou du noeud auriculoventriculaire (AV) a été proposée dans certains cas. La prise en charge des syncopes ou lipothymies par chute tensionnelle d'effort reste décevante. Seuls les patients obstructifs restant sévèrement symptomatiques en dépit d'un traitement médical maximal devraient être évalués pour porter l'indication de procédures invasives, stimulation cardiaque double chambre, AS ou chirurgie. Les taux de complications de l'AS rapportés dans la littérature, essentiellement bloc AV complet, sont supérieurs à 5-10 % avec des taux de mortalité de 0-4 % tandis que les bénéfices à moyen terme paraissent comparables à ceux observés après myectomie. La chirurgie, selon les recommandations récentes, devrait être préférée chez la plupart des jeunes patients obstructifs réfractaires aux médicaments. Alors que la survie globale des patients avec CMH est identique à celle de la population générale, la détection des patients à haut risque de mort subite, notamment les plus jeunes, reste difficile, et les indications de DAI chez les patients à haut risque sans antécédent d'arrêt cardiaque devraient être adaptées à chaque cas et au contexte familial.
Introduction
Hypertrophic cardiomyopathy (HCM) is now recognized as a not uncommon finding in the general population (one per 500 individuals). This discovery, combined with the publication of multiple pivotal studies over the past 20 years concerning the pathophysiology, genetics, natural history and causes of HCM, and the risk factors for death, has led to a better understanding of the disease by the medical community and to an increasing number of patients being diagnosed with HCM [1] . At the same time, the management of patients with HCM has evolved: while medical management and, exceptionally, surgery were the only options for a period of 40 years, electrical therapies including dualchamber (DDD) pacing or implantable cardiac defibrillators (ICDs) and alcohol septal ablation (ASA) have emerged as promising new techniques, with an exponentially rising number of indications. In parallel, whereas primarily clinical cardiologists (and echocardiographists) have been involved in the diagnosis and treatment of HCM, nowadays interventional rhythmologists and interventional cardiologists are progressively taking a role, often being asked for first-line management advice for this condition. Times are therefore changing for patients with HCM, in a manner similar perhaps to that for coronary artery disease when angioplasty emerged as a new therapeutic modality. However, one probably needs to temper excessive enthusiasm and bear in mind some clinically relevant statements before treating these patients. In this report, therefore, we provide an overview of HCM and the treatment options currently being used, and offer suggestions for future clinical research.
While HCM is often a benign disease, sudden death is more frequent in the young
The overall survival of patients with HCM is similar to that of the general population. Moreover, mortality appears to have decreased over the past decades, at a rate of approximately 1-2% per year [1] [2] [3] [4] . Regarding this issue, the primary goal of any treatment in most patients (who are only moderately symptomatic) should be ''primum non nocere'', or ''first, do no harm''.
Studies have shown that three causes of death are predominant in patients with HCM: sudden cardiac death (SCD) due to ventricular arrhythmias (VAs), irrespective of the initial trigger ( Fig. 1 ) [1] [2] [3] [4] [5] ; heart failure often preceded by permanent atrial fibrillation; and stroke in the setting of paroxysmal or permanent atrial fibrillation (2.5% per year) [1] [2] [3] . Bacterial endocarditis remains a real risk, essentially in patients with obstruction. While each cause of death occurs at a frequency of less than 1% per year, the risk of SCD remains markedly elevated in the youngest patients, reaching up to 6% per year in those aged 20-30 years [2] . Moreover, SCD frequently occurs as the first clinical event (in about 75% of all SCDs) in asymptomatic or mildly symptomatic (New York Heart Association [NYHA] functional class I or II) patients, and less frequently during moderate or severe exercise (about 15%, justifying the exclusion of patients from any competitive sport), and sometimes even while the individual is in bed [2] . Mechanisms of sudden cardiac death in hypertrophic cardiomyopathy [1] [2] [3] [4] . While precipitant factors are usual and can be detected by noninvasive screening procedures (Holter electrocardiogram, exercise test, etc.), sustained ventricular tachycardia or primary ventricular fibrillation can be the first and last event [5] .
Detection of patients at high risk of death remains challenging
Among the suggested risk factors for SCD (Table 1) , five have been proposed as major markers, but these are essentially relevant for young adults before the age of 40-50 years:
• family history of premature SCD;
• marked (or malignant) left ventricular hypertrophy (≥ 30 mm); • unexplained syncope or presyncope; • nonsustained ventricular tachycardia (≥ 120 bpm);
• abnormal blood pressure response during upright exercise (< 20-30 mmHg rise during peak exercise; but of no value in children or young adolescents).
While the negative predictive values for each of these markers are high (> 90%), their positive predictive values are low (< 20%), weakening their role in the stratification of risk in individual patients [1, 2] . A multifactorial approach may be more efficient, as the combination of at least three major risk factors (present in only 5% of patients) has helped to identify a subgroup with a markedly elevated risk of SCD (6% per year) [6] .
Other markers have been proposed recently (Table 1) , based on the results from paced electrocardiographic fractionation analysis [7] and cardiac magnetic resonance (CMR). The 5-year probability of SCD given the presence of a fibrous scar on CMR has been estimated to reach approximately 11% versus 0.7% in its absence [8] . It remains that SCD can occur at all ages, in asymptomatic patients with no classical markers of SCD, and even in the absence of left ventricular hypertrophy.
Heart failure is an important cause of death at all ages but particularly in the elderly population; it is accelerated by the development of permanent atrial fibrillation, which is often poorly tolerated in patients with stiff ventricles and sometimes requires rapid cardioversion [9] . An association between the presence of resting obstruction (≥ 30 mmHg) and mortality (twofold at 10 years) has been demonstrated recently, essentially due to a marked increase in the rate (4.4-fold) of progression towards severe functional limitation and death from heart failure [10] . In the same study, the importance of the gradient did not correlate with the incidence of death, while others have suggested an association between elevated left ventricular outflow tract (LVOT) gradient (> 70 mmHg) and death (four-fold) [11] .
Proposed determinants of stroke [3, 9, 12] in HCM are atrial fibrillation, dilated left atrium (exponential rise above 45 mm or 34 mL/cm 2 by echocardiography), advanced age (> 60 years), female sex, LVOT obstruction and existence of a prothrombotic state (hypercoagulation and inflammatory process), which has been noted in patients with HCM, particularly in the obstructive forms [13] . Atrial fibrillation is associated with reduced survival and progression to severe heart failure. Prophylactic anticoagulation is then mandatory in patients with paroxysmal or chronic atrial fibrillation.
Medical therapies targeted to improve quality of life are often underused
In symptomatic patients, when resting and/or exercise LVOT obstruction is present (about 70% of all patients), one first hypothesizes that symptoms are due mainly to the gradient, and the primary aim is therefore to decrease the resting and/or exercise gradient [14] . In fact, even if the resting gradient only poorly correlates with functional limitation, it increases symptoms through reduced stroke volume (leading to syncope), increased left ventricular pressure and microcirculatory abnormalities (leading to angina), increased systolic anterior motion of the mitral valve and mitral regur-gitation and load-dependant diastolic dysfunction (leading to dyspnoea) [15, 16] .
In hypertrophic obstructive cardiomyopathy (HOCM), beta-blockers should be preferred as the first-line therapy (decreasing essentially the provoked gradient) while verapamil should be chosen in patients with contraindications to beta-blockers or in the absence of obstruction (improving diastolic function). A high daily dosage of each drug should be achieved through progressive increases in the dosage, which is scarcely achieved, corresponding to 320-480 mg of propanolol (and up to 600 mg) or 480 mg of verapamil. This progressive approach usually limits the problems of tolerance. Lower dosages may be used when both drugs are prescribed concomitantly. As a third-line therapy, the association of one of the former drugs with disopyramide (200-600 mg), which also decreases contractility and heart rate, is efficient in decreasing the resting gradient when patients remain symptomatic along with the presence of a residual resting gradient. It is also the drug of choice (with amiodarone) to prevent recurrence of atrial fibrillation [15] [16] [17] [18] . Disopyramide appears not to increase mortality [19] , but it should never be used with amiodarone because when combined these drugs have a risk of induced VA. Finally, adjunctive treatment with a low-dose diuretic, which may increase obstruction, is sometimes necessary when exercise dyspnoea persists along with markedly elevated left ventricular end-diastolic pressure (measured invasively or suspected at Doppler echocardiography when the ratio of E-wave velocity at the mitral inflow on E velocity at the mitral annulus exceeds 12-15 cm/s [20] . This incremental and additive approach, while quite efficient and recommended in recent guidelines [15] [16] [17] [18] , is scarcely used in current clinical practice. Only patients with HOCM who remain severely symptomatic (with severe dyspnoea and/or angina, or recurrent syncope) despite maximal medical therapy should be considered for invasive procedures including permanent DDD pacing with a short atrioventricular (A-V) delay, ASA or cardiac surgery [17] .
Indications for electrical therapies should be patient-orientated
With regard to pacing, randomized, controlled studies with relatively short follow-up (3 months on the active DDD mode) have produced controversial results, some in favour of DDD pacing (fewer symptoms and gradient versus AAI mode) [21] . Others, however, show either a moderate positive effect on the gradient but no difference in exercise duration or peak oxygen consumption [22] , or the absence of any positive effect (while the same study reported 40% of responders aged over 65 years) [23] . Thus, the indications of DDD pacing dramatically decreased within the past 10 years. If some patients with HOCM undoubtedly benefit from pacing, clinical or echocardiographic variables fail to predict a positive response to DDD pacing [24] , which is probably critically dependant of the setting of the A-V delay just after implantation and during follow-up. According to recent guidelines, permanent pacing may be considered in medically refractory symptomatic patients with HCM and significant resting or provoked LVOT obstruction (Class IIB, level of evidence: A) [25] . This is even more so in HOCM patients with coexisting advanced conduction system disease with an independent indication for an ICD, or discussion of septal ablation with the presence of left bundle branch block [15] .
With regard to ICDs, rates of interventions for VAs in multicentre HCM registries reach up to 10% per year in patients with a history of aborted SCD and 4% per year in high risk patients without prior cardiac arrest (sometimes up to 10 years after implantation!) [26, 27] . According to the 2008 guidelines from the American College of Cardiology/American Heart Association/Heart Rhythm Society [25] , an ICD should be implanted if the patient has had a prior cardiac arrest (Class I, level of evidence: C), and is reasonable for patients with sustained ventricular tachycardia or if one or more risk factors for SCD is present (IIa, C). It may be considered in patients with syncope in whom invasive and noninvasive investigations have failed to define a cause (IIb, C) or in patients with familial HCM associated with SCD (IIb, C) (level of evidence C means that very limited populations were studied for this purpose). As 25% and 20% of all patients with HCM have only one or two risk factors, respectively [6] , and taking into account that most of these patients will not die suddenly, it would not be reasonable to implant ICDs systematically in this population: instead, management should be patient-and family-orientated. A good example is the adolescent or young adult with a single major risk factor (such as multiple SCDs at a young age in firstdegree relatives or malignant hypertrophy or nonsustained ventricular tachycardia on Holter electrocardiographic monitoring) for whom no definite rules can be provided. One must bear in mind that, in a recent cohort of 506 patients, implantation complications occurred in 27% of cases, with one (0.2%) death linked directly to the procedure [27] . Indications for ICDs in children with HCM are the same as those for adults, with careful consideration of the risks associated with implantation, which increase with small body size [25] .
Alcohol septal ablation might be overused [17]
Since 1994, when Ulrich Sigwart first introduced ASA through the first septal branch into clinical practice [28] , the technique has become an important therapeutic option for severely symptomatic (NYHA class III or IV) patients with HOCM despite maximal medical therapy, with an LVOT gradient greater than or equal to 50 mmHg (either at rest or during or after exercise) and predominant upper septal hypertrophy (≥ 18 mm without important structural abnormalities in the mitral valve) without associated significant coronary atherosclerosis [17] . The increase in number of indications appears to be due to the relative (or apparent) simplicity and wide availability of the technique outside of HCM reference centres, as well as to the important proportion of HCM patients with resting (25%) or exercise-provoked (> 50%) gradient [14] and the less-invasive nature of the technique compared with surgical myectomy.
The ASA technique, which combines coronary angiography with contrast echocardiography, has now been standardized [29] [30] [31] [32] . Contrast echocardiography (usually 1-2 mL of 350 mg/mL solution of Levovist ® injected into the septal artery under echocardiographic control in the apical fourchamber view) helps to identify the core of alcohol accumulation (but underestimates the tissue diffusion of alcohol) and checks for the absence of perfusion of erratic territories (such as the mitral or tricuspid papillary muscles or the right ventricular free wall). While the upper hypertrophied septum is usually perfused by the first septal branch, 5-30% of candidates present a nonsuitable septal branch. Furthermore, in 10-30% of cases, successful ASA necessitates selective administration of alcohol into more than one septal branch, initially or during a second procedure (as is the case for 10% of patients). There has been much discussion concerning the ideal volume and flow rate of alcohol infusion; the initial use of a 2-5 cm 3 infusion over a period of 30 s has been replaced progressively by smaller quantities (about 1-2 cm 3 ) over a longer period (30-60 s), with a slow continuous infusion to avoid A-V block and overspill from the target territory. The balloon is usually kept inflated for at least 5 min after the end of infusion to allow clot organization and prevent vascular runoff of alcohol. A temporary pacemaker needs to be inserted during the procedure, remaining in place for the following 3-4 days as delayed A-V block (10-25% of all procedures) can arise suddenly after 48 h [31] . The favourable effects of ASA typically progress over time in three distinct phases (not observed consistently), with periprocedural abolition of the gradient (coagulation necrosis), early (1-3 days) postprocedural recurrence (edematous phase for 5-10 days) and late permanent decrease of the gradient (scarred and thin myocardium) [31] .
Procedural success, defined as at least 50% reduction in the resting gradient or decreased provoked gradient with residual resting gradient less than 20 mmHg, occurs in more than 80% of cases. Up to 50% of patients are in NYHA class I after the procedure, along with improved exercise capacity and VO 2 peak, decreased septal thickness and ventricular remodelling (decreased mass and increased dimensions) combined with improvement in diastolic function indices, and decreased left atrial size [28, 32, 33] . The complication rates of ASA (Table 2) range from 5% to 30%--essentially complete A-V block (the incidence of which has decreased (> 5-10%) with the use of ultrasonic guidance and lower dose of alcohol)--with mortality rates ranging from 0-4% (mean: 1.9%) [16] . Medium-term follow-up data are now available, and the benefits appear comparable to those observed after myectomy, with an overall mortality-free survival, including ICD discharge for VAs, of 94% at 2 years and 88% at 4 years [15] .
According to recent guidelines, surgical septal myectomy should be the primary treatment option for most severely symptomatic drug-refractory patients with HOCM, particularly in the young, while ASA is an alternative for patients at increased operative risk, for those without access to expert surgical centres or who refuse operation after both options have been discussed fully [15, 34] . Over the past 10 years, surgical mortality related to isolated myectomy has approached 1% in major expert centres, with low procedurerelated morbidity (2-3%), excellent late results (90% improved) and high long-term survival rates [35] . Surgery remains the procedure of choice in cases of associated structural mitral valve abnormalities or coronary artery disease, in patients requiring the Maze procedure to cure atrial fibrillation or eventually in cases of unsuccessful ASA (Table 3) . 
Structural mitral valve abnormalities should be tracked
The presence of intrinsic structural abnormalities of the mitral valve may be responsible for obstruction and mitral regurgitation [36] . These include increased leaflet thickness, surface and length, prolapse and abnormal papillary muscle insertion in about 20% of patients with HOCM [15, 37] . Anterior malposition of the mitral valve apparatus, which is frequent in HCM, together with leaflet elongation, may explain persistence of systolic anterior motion and obstruction after ASA [38, 39] . When important, such abnormalities represent a contraindication to ASA and surgery should be considered, which may include specific procedures targeted to the mitral valve such as valvuloplasty or replacement.
New hopes
In HCM, randomized studies concerning medical therapy, ASA or surgery are lacking due to the relative scarcity of the disease. Angiotensin receptor blockers [40] and statins [41] have shown some efficacy in preventing left ventricular hypertrophy in transgenic animals. Data concerning treatment of syncope or presyncope due to an abnormal blood pressure response during exercise are lacking, but some have proposed the use of a dopamine-receptor antagonist in this setting [42] . Radiofrequency catheter ablation of atrial fibrillation seems to be possible in HCM, with better results in cases of paroxysmal versus permanent atrial fibrillation [43] . However, the risk associated with the technique and recurrence over the medium term should not be ignored, while A-V node ablation with pacemaker implantation may be a safe alternative. As another option to ASA, septal artery embolization with coils has been proposed recently as a less-invasive technique compared with ASA, with a lower rate of complications and A-V block, along with an apparently smaller benefit in the LVOT gradient, probably due to the development of collateral blood flow [44] . Finally, heart transplantation can be performed in patients with HCM and end-stage evolution with systolic dysfunction, with similar results to those from patients with idiopathic dilated cardiomyopathy [45] . Gene therapy remains the ultimate goal as the turnover of sarcomeric proteins is relatively rapid.
